Results 251 to 260 of about 2,901,268 (383)

Phase 3b Extension Study MT‐1186‐A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims An On/Off dosing regimen of intravenous (IV) edaravone and edaravone oral suspension is currently approved in the US for treatment of amyotrophic lateral sclerosis (ALS). Placebo‐controlled clinical trials showed that IV edaravone slows physical functional decline.
Angela Genge   +17 more
wiley   +1 more source

β3‐Adrenoceptor Agonists for Neurogenic Lower Urinary Tract Dysfunction: Evidence and Clinical Rationale for First‐Line Therapy

open access: yesNeurourology and Urodynamics, EarlyView.
ABSTRACT Aims To summarize current evidence on β3‐adrenoceptor agonists for managing neurogenic lower urinary tract dysfunction (NLUTD), focusing on their efficacy, safety, and clinical role in optimizing bladder storage and protecting upper tracts. Methods Evidence from randomized controlled trials, meta‐analyses, and observational studies in spinal ...
Sharon E. Fishberg, Rano Matta
wiley   +1 more source

Chronic constipation

open access: yes, 2020
Alex Soh Yu Sen   +2 more
openaire   +2 more sources

Physiological barriers to oral intake in survivors of critical illness: A scoping review

open access: yesNutrition in Clinical Practice, EarlyView.
Abstract Oral nutrition is the predominant mode of nutrition delivery on the post–Intensive Care Unit (ICU) ward; yet, it is associated with lower intake than via enteral or parenteral nutrition. There are limited data on barriers that influence oral intake in ICU survivors.
Breanna J. Teleki   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy